Large British drug firms echoed these findings: AstraZeneca stated that “continuing uncertainty around Brexit is impacting recruitment for skilled roles”, and Glaxo Smith Kline said that it was “critical” that any new immigration system would enable drug firms to “attract the best, diverse talent in both the UK and EU”2Withers, I. (2018, January 7).